Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: type II DNA topoisomerase inhibitors - Nox Pharmaceuticals

Drug Profile

Research programme: type II DNA topoisomerase inhibitors - Nox Pharmaceuticals

Alternative Names: Adva-27a; Adva-32a; Carbon-difluoro etoposide derivatives - Advanomics/Sunshine Biopharma; Difluoro-Etoposide; Topo2 inhibitors - Advanomics/Sunshine Biopharma; Topoisomerase II inhibitors - Advanomics/Sunshine Biopharma

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanomics
  • Developer NOX Pharmaceuticals
  • Class Antineoplastics; Dioxanes; Dioxolanes; Lactones; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Pancreatic cancer; Small cell lung cancer; Uterine cancer
  • No development reported Cancer

Most Recent Events

  • 18 May 2018 Type II DNA topoisomerase inhibitors are still in preclinical development for Breast cancer, Small cell lung cancer, Uterine cancer and Pancreatic cancer in USA and Canada (Sunshine Biopharma pipeline, May 2018)
  • 15 May 2018 Sunshine Biopharma plans a clinical trial for Pancreatic cancer in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top